Brigham Hospital announced that it will test the first nasal spray for Alzheimer’s disease.
And according to the British newspaper “Express”, the initial experiment will include 16 people with Alzheimer’s, aged between 60 and 85 years.
Participants in the experiment will be given two doses of the spray, once a week.
The researchers believe that stimulating the immune system can help remove beta-amyloid plaques in the brain, which scientists suspect may have a negative role in Alzheimer’s.
Scientific research suggests that if beta-amyloid plaques are not eliminated, which is a type of protein, it accumulates to destroy the synapses that connect cells, leading to a deterioration in cognitive abilities.
The sprayer will spray the drug “Protolin” directly into the nose with the aim of activating the immune cells, with the aim of removing the link between the plaques.
Commenting on the study, Jeffrey Cummings, professor of brain sciences at the University of Nevada, said: “The idea of activating immune cells has become more central to the treatment of Alzheimer’s disease,” adding that nasal sprays “may be better at delivering protein to immune cells compared to other methods such as using an inhaler.” .
Scientists are still trying hard to find out the cause of Alzheimer’s disease, whose symptoms include loss of memory and thinking skills, a decline in verbal abilities, in addition to suffering from insomnia.